CR20140213A - Preparación de liberación sostenida - Google Patents

Preparación de liberación sostenida

Info

Publication number
CR20140213A
CR20140213A CR20140213A CR20140213A CR20140213A CR 20140213 A CR20140213 A CR 20140213A CR 20140213 A CR20140213 A CR 20140213A CR 20140213 A CR20140213 A CR 20140213A CR 20140213 A CR20140213 A CR 20140213A
Authority
CR
Costa Rica
Prior art keywords
sustained release
release preparation
salt
active ingredient
provided containing
Prior art date
Application number
CR20140213A
Other languages
English (en)
Inventor
Yutaka Tanoue
Yusuke Murakawa
Yumiko Ishii
Kaoru Takenaka
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140213(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR20140213A publication Critical patent/CR20140213A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Se proporciona una preparación de liberación sostenida que contiene pioglitazona o una sal de esta como un ingrediente activo y que muestra superior sostenibilidad.
CR20140213A 2011-10-21 2014-05-09 Preparación de liberación sostenida CR20140213A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011232302 2011-10-21

Publications (1)

Publication Number Publication Date
CR20140213A true CR20140213A (es) 2014-06-18

Family

ID=47178262

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140213A CR20140213A (es) 2011-10-21 2014-05-09 Preparación de liberación sostenida

Country Status (29)

Country Link
US (1) US9907789B2 (es)
EP (1) EP2768487B1 (es)
JP (1) JP6093762B2 (es)
KR (1) KR20140081826A (es)
CN (1) CN104039313A (es)
AP (1) AP2014007645A0 (es)
AR (1) AR088398A1 (es)
AU (1) AU2012326976B2 (es)
BR (1) BR112014008744A2 (es)
CA (1) CA2852417A1 (es)
CL (1) CL2014000992A1 (es)
CO (1) CO6960544A2 (es)
CR (1) CR20140213A (es)
DO (1) DOP2014000077A (es)
EA (1) EA201490840A1 (es)
EC (1) ECSP14013328A (es)
IL (1) IL232114A0 (es)
IN (1) IN2014DN03169A (es)
MA (1) MA35717B1 (es)
MX (1) MX2014004679A (es)
NZ (1) NZ624275A (es)
PE (1) PE20141189A1 (es)
SG (2) SG2014012025A (es)
TN (1) TN2014000152A1 (es)
TW (1) TW201323018A (es)
UA (1) UA113858C2 (es)
UY (1) UY34403A (es)
WO (1) WO2013058409A1 (es)
ZA (1) ZA201403103B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987250B2 (en) 2012-04-20 2015-03-24 Gilead Sciences, Inc. Therapeutic compounds

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013058409A1 (en) 2011-10-21 2013-04-25 Takeda Pharmaceutical Company Limited Sustained-release preparation
US20150141517A1 (en) * 2013-11-15 2015-05-21 Shin-Etsu Chemical Co., Ltd. Granulated composite, rapid release tablet and method for producing same
KR102485766B1 (ko) 2019-12-11 2023-01-09 한국유나이티드제약 주식회사 생체이용률이 향상된 피오글리타존 함유 약학조성물

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810502A (en) 1987-02-27 1989-03-07 Alza Corporation Pseudoephedrine brompheniramine therapy
US4820522A (en) 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
JPH0624991A (ja) 1991-06-20 1994-02-01 Tokyo Tanabe Co Ltd ウルソデスオキシコール酸持続性製剤
JPH0624959A (ja) 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
PL175026B1 (pl) * 1992-09-18 1998-10-30 Yamanouchi Pharma Co Ltd Preparat typu hydrożelu o przedłużonym działaniu
JPH06316517A (ja) 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
WO1998056359A2 (de) 1997-06-13 1998-12-17 Roland Bodmeier Zusammensetzungen, die die wirkstofffreisetzung verzögern
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
EP1413315A4 (en) 2001-08-03 2006-08-16 Takeda Pharmaceutical DRUGS WITH CONTINUOUS RELEASE
KR101363679B1 (ko) 2002-09-20 2014-02-14 안드렉스 랩스 엘엘씨 약제학적 정제
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
JP4493970B2 (ja) 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
IN192749B (es) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
US7442387B2 (en) 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
CA2519208A1 (en) 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Controlled release composition
JP4933033B2 (ja) 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
EP1642593A1 (en) 2003-06-06 2006-04-05 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
JP2005015477A (ja) 2003-06-06 2005-01-20 Takeda Chem Ind Ltd 固形製剤
US20060003002A1 (en) 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
EP1738754B1 (en) 2004-04-14 2015-07-15 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
BRPI0514416A (pt) 2004-08-31 2008-06-10 Pfizer Prod Inc formas de dosagem de liberação controlada combinando liberação imediata e liberação controlada de um fármaco de baixa solubilidade
AU2006295007A1 (en) 2005-09-22 2007-04-05 Smithkline Beecham (Cork) Limited Combination of rosiglitazone and donepezil for improvement of cognitive function
WO2007054976A2 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
WO2007072992A2 (en) 2005-12-22 2007-06-28 Takeda Pharmaceutical Company Limited Solid preparation containing an insulin sensitizer
PL2002828T3 (pl) 2006-03-30 2019-11-29 Nippon Zoki Pharmaceutical Co Stały preparat farmaceutyczny
CL2007001195A1 (es) 2006-04-27 2008-01-04 Takeda Pharmaceutical Composicion farmaceutica solida que comprende un nucleo con un compuesto derivado de bencimidazol y una grasa o aceite, una primera capa que comprende un polimero de alto peso molecular que recubre el nucleo y una segunda capa que comprende pioglitazona, util para tratar enfermedades circulatorias.
CN101674811B (zh) 2007-02-09 2015-08-19 阿尔法制药有限公司 含有两种或更多种不同物理形态的活性药物成分的剂型
TW200914006A (en) * 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
CN101269040A (zh) * 2008-05-16 2008-09-24 北京正大绿洲医药科技有限公司 盐酸吡格列酮缓释滴丸及其制备方法
US8445190B2 (en) 2008-09-30 2013-05-21 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
JP5827952B2 (ja) 2009-10-09 2015-12-02 ユンジン・ファーム・カンパニー・リミテッドＹｕｎｇｊｉｎ Ｐｈａｒｍ． Ｃｏ． Ｌｔｄ． 速効性と持続性を同時に有する薬剤学的組成物
JP2011232302A (ja) 2010-04-30 2011-11-17 Ricoh Elemex Corp 画像検査方法及び画像検査装置
CN101884627B (zh) * 2010-07-07 2012-01-25 青岛黄海制药有限责任公司 盐酸吡格列酮胃内滞留缓释片及其制备方法
EP3106165B1 (en) * 2011-01-10 2019-02-27 Zinfandel Pharmaceuticals, Inc. Methods and drug products for treating alzheimer's disease
WO2013058409A1 (en) 2011-10-21 2013-04-25 Takeda Pharmaceutical Company Limited Sustained-release preparation
KR20160056691A (ko) 2014-11-12 2016-05-20 삼성에스디아이 주식회사 이차전지

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987250B2 (en) 2012-04-20 2015-03-24 Gilead Sciences, Inc. Therapeutic compounds
US9096586B2 (en) 2012-04-20 2015-08-04 Gilead Sciences, Inc. Therapeutic compounds

Also Published As

Publication number Publication date
AU2012326976B2 (en) 2017-08-17
JP2014530802A (ja) 2014-11-20
KR20140081826A (ko) 2014-07-01
IL232114A0 (en) 2014-06-30
BR112014008744A2 (pt) 2017-04-18
WO2013058409A1 (en) 2013-04-25
NZ624275A (en) 2016-09-30
US9907789B2 (en) 2018-03-06
SG2014012025A (en) 2014-06-27
AR088398A1 (es) 2014-05-28
SG10201700121YA (en) 2017-03-30
CO6960544A2 (es) 2014-05-30
IN2014DN03169A (es) 2015-05-22
ECSP14013328A (es) 2014-05-31
UA113858C2 (uk) 2017-03-27
ZA201403103B (en) 2015-08-26
JP6093762B2 (ja) 2017-03-08
MA35717B1 (fr) 2014-12-01
US20140248362A1 (en) 2014-09-04
AP2014007645A0 (en) 2014-05-31
UY34403A (es) 2013-05-31
CL2014000992A1 (es) 2014-09-05
CN104039313A (zh) 2014-09-10
MX2014004679A (es) 2014-08-01
EP2768487B1 (en) 2020-06-03
TN2014000152A1 (en) 2015-09-30
AU2012326976A2 (en) 2014-06-12
EP2768487A1 (en) 2014-08-27
AU2012326976A1 (en) 2014-05-29
CA2852417A1 (en) 2013-04-25
DOP2014000077A (es) 2014-07-15
EA201490840A1 (ru) 2014-08-29
PE20141189A1 (es) 2014-09-24
TW201323018A (zh) 2013-06-16

Similar Documents

Publication Publication Date Title
CY2019031I2 (el) Αναπνευστικη απελευθερωση ενεργων παραγοντων
CL2014002700A1 (es) Composición herbicida que comprende como ingrediente activo, un compuesto de uracilo
AR093645A1 (es) Una formulacion estabilizada de pemetrexed
CO6811868A2 (es) Combinaciones de principios activos
UY34772A (es) ?una formulación de fármaco de liberación retardada?.
HK1199418A1 (en) Formulations of active agents for sustained release
CR11583A (es) Arilpirrolinas insecticidas
BR112013008601A2 (pt) formulações de emulsão de clevidipina contendo agentes antimicrobianos
CO6870038A2 (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
CO6801696A2 (es) Artículo absorbente que incluye una composición reguladora
CR20140334A (es) Forma galénica divisible que permite una liberación modificada del principio activo
CO6852077A2 (es) Composiciónes que comprenden ditiínas sustituidas fungicidas y compuestos activos adicionales
BR112014003027A2 (pt) formulação herbicida melhorada
UY33549A (es) Quinolil aminas como agentes inhibidores de las quinasas
CL2015000091A1 (es) Apósitos con una liberación prolongada de agentes activos.
UY34222A (es) Partículas que comprenden un principio activo a base de poliacrilato
CO6970610A2 (es) Suspoemulsiones estables formadas por una pluralidad de ingredientes agrícolamente activos
ZA201208286B (en) Use of formulations having insecticidal activity
ZA201404035B (en) Microcapsule containing fungicidal active ingredient
CR20140213A (es) Preparación de liberación sostenida
CR20120521A (es) Combinaciones de principios activos
CO6811851A2 (es) Formulación que comprende derivado de fenilaminopirimidina como agente activo
BR112014013613A2 (pt) composição antimicrobiana, método de desinfecção de uma superfície e uso de uma composição
CR20130520A (es) Composición herbicida que comprende flazasulfuron y metribuzina
CO6990742A2 (es) Composición herbicida que contiene fluroxipir y glifosato